ClinicalTrials.gg
CompletedNCT00318552Updated Sep 1, 2017

Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

A Phase 4 interventional study of Meropenem in Sepsis, sponsored by Pfizer. Completed at 12 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing meropenem in Sepsis — 4 open to participants now, 5 under way, 1 of them phase 3. Meropenem · Sepsis.

Enrollment
9th of 16
160 · median 190
Started
2002
the only one that year
Phase 4
7 of 16
3 open now
Registered
1st of 16
by date

Among the 16 studies testing meropenem in Sepsis, this one is the 9th largest by enrollment, is the only one that started in 2002, is one of 7 in phase 4, and was the 1st registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 542 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 16 studies testing meropenem in Sepsis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About meropenem

Meropenem: first FDA approval 1996 (MERREM IV), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing meropenem in Sepsis, or all of them as a file.
02

Study summary

This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Antibiotic Therapy
  • sepsis treatment
  • Meropenem
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female subjects aged ≥ 18, requiring intensive care treatment related to secondary nosocomial sepsis, who require potent broad spectrum intravenous antibiotic therapy.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Number of days from randomization to recovery from sepsis among those patients who survived the trial period

  2. Endpoint considered in conjunction with observed mortality rates to determine whether any reduction in time to recovery from sepsis

Secondary outcomes

  1. Number of days from randomization to ready to discharge from the ICU

  2. Number of days from randomization until patient is discharged from the ICU

  3. Number of days on first line antibiotic therapy

  4. Number of days from randomization until patient is discharged from hospital

  5. Proportion of patients who achieve clinical cure from sepsis following first line antibiotic therapy

  6. Proportion of all patients who are ready to discharge from the ICU following antibiotic therapy

  7. Mortality rate due to "all causes" in the meropenem group and the standard antibiotic therapy group

  8. Mortality rate due to infection in the meropenem group and the standard antibiotic therapy group

  9. Health Economics-Resource utilization for main treatment and diagnostic procedures, tools and materials

07

Study locations

12 sites
  • Research Site
    Baja, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Eger, Hungary
  • Research Site
    Kecskemet, Hungary
  • Research Site
    Kistarcsa, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Pecs, Hungary
  • Research Site
    Siofok, Hungary
  • Research Site
    Szekesfehervar, Hungary
  • Research Site
    Szolnok, Hungary
  • Research Site
    Szombathely, Hungary
  • Research Site
    Veszprem, Hungary
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2006
First posted
Apr 27, 2006
Start
Jan 2002
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00318552
Lead sponsor
Pfizer
First posted
Apr 27, 2006
Start date
Jan 2002
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Sep 1, 2017

Study contacts

AstraZeneca CRR Central and Eastern Europe, Hungary Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meropenem

Start the discussion